RPG Life Sciences Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
- April 28, 2026
- Posted by: Ekta Dhawan
- Category: News
With RPG Life Sciences trading at a current market price of Rs 1650 against a 52-week high of Rs 2650 and a 52-week low of Rs 1250, the Q4 FY26 results will be a pivotal data point for investors deciding on their position. Analyst estimates for Q4 FY26 revenue stand at Rs 305 to 330 Cr, with PAT expectations of Rs 46 to 54 Cr and margin projections of 16 to 18%. Get free investment predictions and live Q4 result alerts on Univest.
This article covers the RPG Life Sciences Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions about RPG Life Sciences ahead of its Q4 FY26 results.
RPG Life Sciences Q4 Results 2026 Date
Get free investment predictions on Univest.
RPG Life Sciences has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. The trading window for designated employees is closed until 48 hours after the results announcement, as per SEBI regulations. Here is how the broader Q4 FY26 earnings calendar looks for select Indian companies in April and May 2026:
| Company | Q4 FY26 Results Date |
|---|---|
| TCS | April 9, 2026 (Declared) |
| RPG Life Sciences | May 2026 (Expected) |
Source: BSE/NSE exchange filings, April 2026. Expected dates may change. Verify before relying.
Why This Quarter Matters for RPG Life Sciences
RPG Life Sciences enters Q4 FY26 with expectations of meaningful year-on-year improvement in its core Pharma Specialty Generics business. Q4 is typically a seasonally important quarter as companies execute on year-end targets, government orders pick up, and annual dividend recommendations are made. For RPG Life Sciences specifically, Q4 FY26 matters because it sets the baseline for FY27 estimates and determines full-year FY26 performance.
Every quarterly result tells a story, but RPG Life Sciences’s Q4 FY26 print will be watched closely because it sets the baseline for FY27 estimates, determines full-year FY26 performance, and provides the first clear read on whether the business momentum is accelerating or decelerating. Management guidance on margins, volumes, and capital allocation will be just as important as the headline PAT number. Screen RPG Life Sciences fundamentals on the Univest Screener.
RPG Life Sciences Q4 FY26 Earnings Estimates
Access premium SEBI-registered research on Univest.
Brokerages including MOFSL, YES Securities, JM Financial, and others have published their Q4 FY26 preview estimates for RPG Life Sciences. The consensus expects Rs 305 to 330 Cr in revenue for Q4 FY26, compared to Rs 285 Cr in Q3 FY26. Profit after tax (PAT) is estimated at Rs 46 to 54 Cr, with margin expectations of 16 to 18%.
| Metric | Q3 FY26 Actual | Q4 FY26 Estimate | YoY Trend |
|---|---|---|---|
| Revenue | Rs 285 Cr | Rs 305 to 330 Cr | Sequential growth expected |
| PAT (Net Profit) | Rs 42 Cr | Rs 46 to 54 Cr | Improvement anticipated |
| EBITDA Margin | 14.7% | 16 to 18% | Stable to marginal improvement |
| Revenue Growth Driver | Core business execution | Seasonal uptick plus order execution | Positive |
| Dividend Expectation | As per FY26 policy | Final dividend possible | Board discretion |
RPG Life Sciences enters Q4 FY26 with expectations of Rs 305 to 330 Cr in revenue driven by execution on existing orders and seasonal demand pickup. Management commentary on the pipeline and deal wins will set the direction for FY27 estimates. Screen RPG Life Sciences fundamentals on the Univest Screener.
5 Key Factors That Will Drive RPG Life Sciences Q4 FY26 Performance
1. Revenue Execution and Order Book Conversion
RPG Life Sciences enters Q4 FY26 with a focus on executing on its existing order book and converting pipeline into recognised revenue. Q4 is seasonally important for the Pharma Specialty Generics sector and the ability to deliver on committed orders will be the first performance test. Analysts expect Rs 305 to 330 Cr in revenue for Q4 FY26. A beat here would signal improving execution capability and set a strong base for FY27 guidance. Track live revenue updates on the Univest Screener.
2. Margin Recovery and Cost Control
Q4 FY26 margin expectations are 16 to 18% versus 14.7% in Q3 FY26. Input cost trends, employee expense efficiency, and pricing power in key markets will collectively determine whether RPG Life Sciences can sustain or improve on Q3 margins. Any margin beat here would be a meaningful positive catalyst for the stock and for FY27 earnings visibility.
3. Final Dividend and Capital Allocation Signals
Q4 board meetings are typically when companies announce their final dividend for the fiscal year. RPG Life Sciences’s capital allocation stance, including whether it maintains, increases, or skips the final dividend, will signal management confidence in the business outlook. A higher-than-expected dividend payout would be a positive surprise for income-focused investors tracking the RPG Life Sciences Q4 results 2026.
4. FY27 Management Guidance
Investors should monitor revenue versus Rs 305 to 330 Cr and PAT versus Rs 46 to 54 Cr as the two primary watchpoints. If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter in the current environment. Get SEBI-registered research on Univest.
5. Sector Tailwinds and Macro Environment
The Pharma Specialty Generics sector in India is benefiting from structural demand drivers including government capex, domestic consumption recovery, and a supportive policy environment. RPG Life Sciences’s ability to translate these sector tailwinds into quarterly earnings growth will be closely watched by institutional investors. The RBI rate cut cycle that commenced in 2026 has also reduced borrowing costs across the sector, providing a further boost to profitability.
5 Risks to Watch in RPG Life Sciences Q4 FY26
1. Revenue Miss Risk
If revenue comes in below the Rs 305 to 330 Cr estimate range, it would signal execution challenges in the Pharma Specialty Generics business. A miss at the revenue line typically triggers a cascading impact on PAT and margin, amplifying the negative reaction in the stock price.
2. FII Selling Pressure
FIIs sold Rs 22,000 crore in Indian equities in a single week following the US tariff announcement in early April 2026. Continued selling would create headwinds for RPG Life Sciences regardless of company-specific fundamentals. With global risk appetite still cautious, institutional positioning remains a key external risk for the stock heading into Q4 results.
3. Margin Compression Risk
Input cost inflation, wage increases, and pricing pressure in key markets could compress RPG Life Sciences’s margins below the 16 to 18% estimate. Any margin miss combined with a revenue miss creates a double negative that typically leads to sharp post-results corrections. Monitor margin trends on the Univest Screener.
4. Regulatory and Policy Risks
The Pharma Specialty Generics sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect RPG Life Sciences’s profitability beyond current consensus models. Any negative regulatory development announced alongside the Q4 results could weigh on investor sentiment.
5. Weak FY27 Guidance Risk
Even if Q4 FY26 numbers come in line with estimates, a below-consensus FY27 guidance from management would be the single biggest negative catalyst. The market prices stocks on forward earnings, and a guidance cut would compress the valuation multiple applied to RPG Life Sciences’s earnings, pushing the stock lower despite an acceptable reported quarter.
RPG Life Sciences Share Price and Analyst Ratings
RPG Life Sciences is trading at Rs 1650 as of April 2026, against a 52-week high of Rs 2650 and 52-week low of Rs 1250. The stock has a market capitalisation of approximately Rs 3200 Cr. Download the Univest iOS App or Univest Android App for live RPG Life Sciences Q4 result alerts and SEBI-registered research.
| Brokerage | Rating | Target Price | Key Thesis |
|---|---|---|---|
| MOFSL | Buy | Rs 2100 | RPG Life Sciences Pharma Specialty Generics sector growth outlook FY27 |
| YES Securities | Buy | Rs 2050 | RPG Life Sciences Pharma Specialty Generics sector growth outlook FY27 |
| Emkay | Buy | Rs 2000 | RPG Life Sciences Pharma Specialty Generics sector growth outlook FY27 |
Conclusion
RPG Life Sciences Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma Specialty Generics sector. Analysts project PAT of Rs 46 to 54 Cr and revenue of Rs 305 to 330 Cr. FY27 guidance will be the most critical post-results catalyst alongside the headline Q4 numbers. For more Q4 FY26 previews, visit Univest Blogs.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.
Frequently Asked Questions
What is the RPG Life Sciences Q4 results 2026 date?
The RPG Life Sciences Q4 results 2026 date is May 2026 (Expected). The board of directors will meet on this date to approve the audited financial results for the quarter and full year ended March 31, 2026.
What is the RPG Life Sciences Q4 FY26 PAT estimate?
Analyst consensus estimates RPG Life Sciences Q4 FY26 PAT at Rs 46 to 54 Cr, based on revenue of Rs 305 to 330 Cr and margin of 16 to 18%. The actual number will be declared on May 2026 (Expected).
What is RPG Life Sciences’s share price ahead of Q4 results?
RPG Life Sciences is trading at Rs 1650 ahead of Q4 FY26 results. The 52-week high is Rs 2650 and the 52-week low is Rs 1250. The market cap is approximately Rs 3200 Cr. Track live price on the Univest Screener.
Will RPG Life Sciences declare a dividend in Q4 2026?
The RPG Life Sciences board may consider a final dividend for FY26 at its Q4 results board meeting on May 2026 (Expected). Dividend decisions are at board discretion and depend on the company’s profitability and cash flow position for the full year. Track dividend announcements on NSE or the Univest Screener.
Which analysts have a Buy rating on RPG Life Sciences?
MOFSL (Target: Rs 2100), YES Securities (Target: Rs 2050), Emkay (Target: Rs 2000). Analyst ratings and target prices change frequently. Always verify the latest ratings on the Univest Screener.
What were RPG Life Sciences Q3 FY26 results?
RPG Life Sciences reported revenue of Rs 285 Cr and PAT of Rs 42 Cr in Q3 FY26, with an operating margin of 14.7%. The Q4 FY26 results on May 2026 (Expected) will provide the next quarterly update. Get detailed financial analysis on Univest.
When does TCS announce Q4 results 2026?
TCS declared Q4 FY26 results on April 9, 2026. Find the full TCS Q4 FY26 analysis on Univest Blogs.
Is RPG Life Sciences a good investment ahead of Q4 results?
Whether RPG Life Sciences is a good investment ahead of Q4 FY26 results depends on your investment horizon and risk appetite. At Rs 1650, the stock is trading at a discount to its 52-week high of Rs 2650. Analyst consensus targets range from Rs 2000 to Rs 2100. Always consult a SEBI-registered financial advisor before making any investment decision. Get free research on Univest.
Recent Article
Mangalam Cement Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
NESCO Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Madhurima Plantation Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Moser Baer India Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Mopeds Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
